Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

VXRT

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.

Oral Vaccine Focused Penny Stock Vaxart Is &#39;Uniquely Positioned&#39;, Analyst Sees Almost 83% Upside

Penny,Stock,Investments,Taking,Off,Concept

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

CLOV

GLYC

$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying

COVID-19

After-Hours Center

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company&#39;s cash runway into 2026.

Vaxart Stock Is Moving Higher After The Bell: What&#39;s Going On?

Vaxart Inc

Earnings

Press Releases

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Management

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Anixa Biosciences

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Seres Therapeutics

Macrogenics

Nkarta

Renovaro

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

Tenaya Therapeutics

Vor Biopharma

XBiotech

Oppenheimer

B. Riley Securities

Cantor Fitzgerald

Comments

Vaxart

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga